[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"bleeding-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:bleeding-disorders":29},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,78],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100624549","ex-vivo-reproduction-of-minimally-invasive-surgery-with-hematoma-lysis-using-modified-tissue-plasminogen-activator-for-intracerebral-hemorrhage-100624549",false,"NCT07411079","Ex Vivo Reproduction of Minimally Invasive Surgery With Hematoma Lysis Using Modified Tissue Plasminogen Activator for Intracerebral Hemorrhage","Ex Vivo Reproduction of Minimally Invasive Surgery With Hematoma Lysis Using Modified Tissue Plasminogen Activator to Improve Parenchymal Clearance in Intracerebral Hemorrhage","MIMICK-TIPITCH","Inclusion Criteria:\n\n* Adult participants (≥ 18 years of age)\n* Able and willing to provide written informed consent\n* Receiving routine outpatient care\n* Either:\n* Without identified hemorrhagic risk (control subjects)\n* With a predefined hemorrhagic risk profile, including antithrombotic treatment, inherited bleeding disorders, thrombocytopenia or conditions requiring reversal or correction of coagulation abnormalities\n* Able to undergo a single additional whole blood collection (30 mL) during a routine clinical visit\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years\n* Inability or unwillingness to provide written informed consent\n* Contraindication to venipuncture or blood sampling\n* Known human immunodeficiency virus (HIV) infection\n* Breastfeeding\n* Presence of an additional coagulation abnormality not related to the identified hereditary bleeding disorder or the antithrombotic treatment under study\n* Individuals deprived of liberty by judicial or administrative decision\n* Individuals under legal protection (guardianship or curatorship)",true,"ALL","18 Years","65 Years",{"count":22,"type":23},1126,"ESTIMATED","OBSERVATIONAL","Intracerebral hemorrhage (ICH) is associated with high mortality and long-term disability, and effective treatment options remain limited. Minimally invasive surgical approaches combined with local administration of thrombolytic agents have been investigated to facilitate hematoma evacuation; however, incomplete clot removal remains frequent, particularly in patients with conditions associated with increased hemorrhagic risk.\n\nThis observational, cross-sectional study uses an ex vivo model of clinically sized intracerebral hematomas generated from whole blood samples collected from control subjects without hemorrhagic risk and from individuals with predefined hemorrhagic risk profiles, including conditions associated with antithrombotic treatment, inherited bleeding disorders, thrombocytopenia and situations involving reversal or correction of coagulation abnormalities.\n\nUsing standardized ex vivo hematoma formation and catheter-based administration of modified Tissue Plasminogen Activator (rtPA), the study will characterize clot structure, composition, and permeability across hemorrhagic risk conditions. The study will then determine personalized dosing regimens of modified rtPA in conditions where thrombolytic activity differs from reference values observed in healthy control samples treated with a standard dose. Finally, the thrombolytic activity of personalized dosing regimens will be evaluated by measuring hematoma weight reduction 9 hours after treatment and compared with predefined efficacy and safety reference boundaries.\n\nThe results of this study are intended to improve understanding of the ex vivo thrombolytic performance of modified rtPA across different hemorrhagic risk contexts and to support future translational and clinical research in intracerebral hemorrhage.",[27,28,29],"Intracerebral Hemorrhage","Hemorrhagic Risk Conditions","Bleeding Disorders",[31,32,33,29,34,35],"Intracranial Hemorrhages","Hematoma Lysis","Modified Tissue Plasminogen Activator","Antithrombotic Therapy","Ex vivo Model","RECRUITING","2026-05-18",{"date":39,"type":40},"2026-05-19","ACTUAL",{"date":42,"type":40},"2026-03-02",{"date":44,"type":23},"2029-03",{"name":46,"class":47},"University Hospital, Lille","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":18,"minAge":57,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":48},"100599368","impact-of-iv-iron-on-bleeding-symptoms-in-iron-deficient-patients-with-inherited-bleeding-disorders-100599368","NCT07083583","Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders","Impact of IV Iron on Bleeding Symptoms in Iron Deficient Patients With Inherited Bleeding Disorders: a Single-arm Prospective Observational Study","IRON-BD","Inclusion Criteria:\n\n1. Males and Females \\> 15 years of age\n2. Diagnosed with an Inherited Bleeding Disorder (Von Willebrand disease, platelet disorders, factor deficiencies, or bleeding disorder of unknown cause)\n3. Evidence of Iron Deficiency (Ferritin \\\u003C 50 ng\u002FmL)\n4. Receiving IV iron at Hemophilia Center of Western Pennsylvania\n5. Willingness to have blood drawn\n6. Willing to return to clinic 3 months post infusion for final blood draw, bleeding and quality of life assessments.\n\nExclusion Criteria:\n\n1. Previous thrombosis, VTE History.\n2. Platelet count \\\u003C 100,000 \\* 109\u002FL\n3. Concomitant use of antiplatelet drugs, anticoagulants, aspirin, NSAIDs.","15 Years",{"count":59,"type":23},40,"This is a prospective, single-arm, single-center observational study evaluating the impact of intravenous (IV) iron replacement in patients with inherited bleeding disorders and iron deficiency (ferritin \\\u003C50ng\u002FdL). Subjects will undergo baseline bleeding assessments, quality-of-life measures, and laboratory tests before receiving standard-of-care IV iron. Follow-up blood work and questionnaires will be conducted post-replacement to assess for changes",[29,62,63,64],"Iron","Platelet","Bleeding",[66,67,68],"Iron deficiency","bleeding disorder","platelet function","2025-10-01",{"date":71,"type":40},"2025-10-03",{"date":73,"type":40},"2025-08-08",{"date":75,"type":23},"2027-10-01",{"name":77,"class":47},"Nicoletta C Machin",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":86,"targetDuration":88,"studyType":24,"phases":4,"briefSummary":89,"conditions":90,"keywords":105,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":48},"100608743","high-altitude-hematology-observation-stem-cell-transplantation-halo-sct-100608743","NCT07205523","High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)","High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT): A Prospective Real-World Cohort Study in the Qinghai-Tibet Plateau","HALO-SCT","Inclusion Criteria:\n\n1. Patients diagnosed with hematologic diseases who are admitted to the HSCT center of Qinghai University Affiliated Hospital on or after September 1, 2023.\n2. Planned or actual hematopoietic stem cell transplantation (HSCT).\n3. Provision of signed informed consent.\n\nExclusion Criteria:\n\n1. Inability to provide long-term follow-up data due to severe comorbidities or logistical reasons.\n2. Substance abuse compromising adherence.\n3. Any condition judged by investigators to jeopardize safety or compliance.",{"count":87,"type":23},1000,"100 Years","The High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT) study is the first prospective real-world cohort of hematologic diseases and transplantation in the Qinghai-Tibet Plateau. Patients undergoing hematopoietic stem cell transplantation (HSCT) at Qinghai University Affiliated Hospital, together with their donors, are systematically enrolled. The registry collects demographic, diagnostic, treatment, prognosis, and medical expense information, as well as biospecimens for future analyses. Historical data are incorporated, and prospective data collection is ongoing with long-term follow-up planned. The registry is designed as a sustainable research infrastructure to provide comprehensive data on disease incidence, treatment patterns, outcomes, and resource utilization in a high-altitude setting.",[91,92,93,94,95,96,97,98,99,100,29,101,102,103,104],"Hematopoietic Stem Cell Transplantation (HSCT)","Acute Myeloid Leukemia (AML)","Leukemias, Acute Myeloid","Myeloid Leukemias, Acute","Hemophilia","Myelodysplastic Syndrome","MDS","Lymphoma","Leukemia","Aplastic Anemia","Bone Marrow Transplantation","Multiple Myeloma","Myeloma, Multiple","Immune Reconstitution",[106],"High-altitude Bone marrow transplantation Allogeneic HSCT Autologous HSCT Immune reconstitution Graft-versus-host disease Relapse Survival Quality of life","2025-09-25",{"date":71,"type":40},{"date":110,"type":40},"2023-09-01",{"date":112,"type":23},"2100-12-31",{"name":114,"class":47},"Yigeng Cao,MD,PhD"]